Immutep


Soluble LAG-3

image Immutep S.A. announced today the publication of a research paper showing that a soluble human LAG-3 protein amplifies the in vitro generation of type 1 tumor-specific immunity.

The study (Cancer Research 2006; 66: (8): 4450-60) was carried out by Chiara Castelli and coworkers in Pr. Giorgio Parmiani's group of Italy's National Tumor Institute in Milan. This group has belonged to the top tier of European tumor immunology groups for more than 20 years, in terms of both basic and clinical research activities.

Click to read the complete Press Release (PDF Format).


Published 05/2006 by admin@immutep.com
© 2002 Immutep, S.A.
Press Release
10/2008 - IMP321 IND Allowance in Pancreatic Cancer
image Immutep S.A. announced today that the FDA, after review of the ...
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy
image Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer
image Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients
image Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I
image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...